| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
3,280,000 |
| Market
Cap: |
1.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3437 - $4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. Co.'s primary investigational product is the LOMECEL-B™ cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. Co. is sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer's disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome, and hypoplastic left heart syndrome.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
297,872 |
322,872 |
322,872 |
322,872 |
| Total Buy Value |
$699,999 |
$734,301 |
$734,301 |
$734,301 |
| Total People Bought |
3 |
6 |
6 |
6 |
| Total Buy Transactions |
5 |
9 |
9 |
9 |
| Total Shares Sold |
0 |
0 |
23,532 |
219,987 |
| Total Sell Value |
$0 |
$0 |
$81,541 |
$1,060,824 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
3 |
10 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• • – |
2024-04-11 |
4 |
B |
$2.35 |
$24,999 |
D/D |
10,638 |
19,616 |
0.01 |
- |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2024-04-11 |
4 |
B |
$2.35 |
$100,000 |
D/D |
42,553 |
633,280 |
0.01 |
- |
|
| Soffer Rock |
|
– • – |
2024-04-11 |
4 |
B |
$2.35 |
$75,000 |
D/D |
31,915 |
208,534 |
0.01 |
- |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2024-04-10 |
4 |
B |
$2.35 |
$250,000 |
D/D |
106,383 |
590,727 |
0.01 |
- |
|
| Soffer Rock |
|
– • – |
2024-04-10 |
4 |
B |
$2.35 |
$250,000 |
D/D |
106,383 |
176,619 |
0.01 |
- |
|
| Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• • – |
2024-03-12 |
4 |
D |
$0.54 |
$17,748 |
D/D |
(32,866) |
89,777 |
|
- |
|
| Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• • – |
2024-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
80,200 |
122,643 |
|
- |
|
| Ross Cathy |
|
– • – |
2024-01-10 |
4 |
B |
$1.31 |
$6,545 |
D/D |
5,000 |
10,000 |
0.01 |
-73% |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2024-01-02 |
4 |
D |
$1.32 |
$1,309 |
D/D |
(992) |
142,406 |
|
- |
|
| Locklear Lisa |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
D |
$1.32 |
$5,409 |
D/D |
(4,098) |
36,824 |
|
- |
|
| Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
D |
$1.32 |
$6,762 |
D/D |
(5,123) |
42,443 |
|
- |
|
| Agafonova Nataliya |
Chief Medical Officer |
• – – |
2024-01-02 |
4 |
D |
$1.32 |
$4,058 |
D/D |
(3,074) |
20,786 |
|
- |
|
| Baluch Khoso |
|
– • – |
2023-12-29 |
4 |
B |
$1.43 |
$11,915 |
D/D |
8,322 |
15,000 |
0.01 |
-75% |
|
| Baluch Khoso |
|
– • – |
2023-12-28 |
4 |
B |
$1.40 |
$2,342 |
D/D |
1,678 |
6,678 |
0.01 |
-75% |
|
| Pfeffer Jeffrey |
|
– • – |
2023-12-28 |
4 |
B |
$1.35 |
$13,500 |
D/D |
10,000 |
15,000 |
0.01 |
-75% |
|
| Agafonova Nataliya |
Chief Medical Officer |
• – – |
2023-10-02 |
4 |
D |
$2.29 |
$7,005 |
D/D |
(3,059) |
23,860 |
|
- |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2023-10-02 |
4 |
D |
$2.29 |
$1,866 |
D/D |
(815) |
143,398 |
|
- |
|
| Locklear Lisa |
Chief Financial Officer |
• – – |
2023-10-02 |
4 |
D |
$2.29 |
$9,339 |
D/D |
(4,078) |
40,922 |
|
- |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2023-09-21 |
4 |
OE |
$3.00 |
$15,000 |
D/D |
5,000 |
7,828,263 |
|
- |
|
| Lehr Paul T |
General Counsel, Secretary |
• – – |
2023-09-20 |
4 |
OE |
$3.00 |
$6,000 |
D/D |
2,000 |
144,213 |
|
- |
|
| Hare Joshua |
Chief Scientific Officer |
• • • |
2023-09-12 |
4 |
OE |
$3.00 |
$90,000 |
D/D |
30,000 |
7,823,263 |
|
- |
|
| Locklear Lisa |
Chief Financial Officer |
• – – |
2023-09-12 |
4 |
A |
$3.00 |
$15,000 |
D/D |
5,000 |
45,000 |
|
- |
|
| Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• – – |
2023-09-12 |
4 |
OE |
$3.00 |
$30,000 |
D/D |
10,000 |
47,566 |
|
- |
|
| Soffer Rock |
|
– • – |
2023-09-08 |
4 |
OE |
$3.00 |
$90,000 |
D/D |
30,000 |
702,351 |
|
- |
|
| Hashad Mohamed Wael Ahmed |
Chief Executive Officer |
• – – |
2023-09-01 |
4 |
D |
$2.64 |
$11,413 |
D/D |
(4,323) |
37,566 |
|
- |
|
64 Records found
|
|
Page 1 of 3 |
|
|
